IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway

BACKGROUND: Cancer cachexia as a metabolic syndrome can lead to at least 25% of cancer deaths. The inhibition of muscle atrophy is a main strategy to treat cancer cachexia. In this process, myostatin (MSTN) can exert a dual effect on protein metabolism, including inhibition of protein biosynthesis a...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Dong, Qiao, Xinran, Ge, Zhijuan, Shang, Yue, Li, Yi, Wang, Wendie, Chen, Minghua, Si, Shuyi, Chen, Shu-zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437903/
https://www.ncbi.nlm.nih.gov/pubmed/30922397
http://dx.doi.org/10.1186/s13395-019-0193-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437903/
https://www.ncbi.nlm.nih.gov/pubmed/30922397
http://dx.doi.org/10.1186/s13395-019-0193-2

Ejemplares similares